



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Xiang-Yang Han *et al.*

Serial No.: 10/672,300

Filed: September 26, 2003

For: DIAGNOSIS OF INVASIVE MOLD
INFECTION

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTXC:766US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS MISSING PARTS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

April 22, 2004

Date


Sharon A. Beresford

INFORMATION DISCLOSURE STATEMENT

MS MISSING PARTS

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTXC:766US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Sharon A. Beresford
Reg. No. 52,615
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 22, 2004

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTXC:766US

10/672,300

List of Patents and Publications for Applicant's

Applicant

Xiang-Yang Han *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

September 26, 2003

Group:

1645

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	"Brief Reports," <i>Clin. Infect. Dis.</i> , 31:181-204, 2000.
	C2	Ascioglu <i>et al.</i> , "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus," <i>Clin. Infect. Dis.</i> , 34:7-14, 2002.
	C3	Baddley <i>et al.</i> , "Invasive mold infections in allogeneic bone marrow transplant recipients," <i>Clin. Infect. Dis.</i> , 32(9):1319-1324, 2001.
	C4	Boom <i>et al.</i> , "Rapid and simple method for purification of nucleic acids," <i>J. Clin. Microbiol.</i> , 28:495-503, 1990.
	C5	Bowman <i>et al.</i> , "Quantitative PCR assay to measure aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate," <i>Antimicrob. Agents Chemother.</i> , 45(12):3474-3481, 2001.
	C6	Brakhage and Langfelder, "Menacing mold: the molecular biology of aspergillus fumigatus," <i>Annu. Rev. Microbiol.</i> , 56:433-455, 2002.
	C7	Bretagne <i>et al.</i> , "Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis," <i>Clin. Infect. Dis.</i> , 26:1407-1412, 1998.
	C8	Einsele <i>et al.</i> , "Detection and identification of fungal pathogens in blood by using molecular probes," <i>J. Clin. Microbiol.</i> , 35(6):1353-1360, 1997.

25354440.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTXC:766US	Serial No. 10/672,300
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Xiang-Yang Han <i>et al.</i>	
		Filing Date: September 26, 2003	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Fahle <i>et al.</i> , "Comparison of six commercial DNA extraction kits for recovery of cytomegalovirus DNA from spiked human specimens," <i>J. Clin. Microbiol.</i> , 38(10):3860-3863, 2000.
	C10	Hebart <i>et al.</i> , "Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening," <i>J. Infect. Dis.</i> , 181:1713-1719, 2000.
	C11	Higuchi <i>et al.</i> , "Kinetic PCR analysis: real-time monitoring of DNA amplification reactions," <i>Biotechnology</i> , 11(9):1026-1030, 1993.
	C12	Latgé, "Aspergillus fumigatus and aspergillosis," <i>Clin. Microbiol. Rev.</i> , 12(2):310-350, 1999.
	C13	Maertens <i>et al.</i> , "Screening for circulating galactomannan as a noninvasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation," <i>Blood</i> , 97(6):1604-1610, 2001.
	C14	Oliveria <i>et al.</i> , "Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole," <i>Braz. J. Med. Biol. Res.</i> , 35(7):789-798, 2002.
	C15	Paterson and Singh, "Invasive aspergillosis in transplant recipients," <i>Medicine</i> , 78(2):123-138, 1999.
	C16	Stynen <i>et al.</i> , "A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis," <i>J. Clin. Microbiol.</i> , 33(2):497-500, 1995.
	C17	Tarrand <i>et al.</i> , "Diagnosis of invasive septate mold infections: a correlation of microbiological culture and histologic or cytologic examination," 38 th Annual Meeting of the Infectious Diseases Society of America (IDSA), abstract #276, 2000.
	C18	Van Burik <i>et al.</i> , "Panfungal PCR assay for detection of fungal infection in human blood specimens," <i>J. Clin. Microbiol.</i> , 36(5):1169-1175, 1998.
	C19	Vogeser <i>et al.</i> , "Postmortem analysis of invasive aspergillosis in a tertiary care hospital," <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> , 16:1-6, 1997.
	C20	Williamson <i>et al.</i> , "Diagnosis of invasive aspergillosis in bone marrow transplant recipients by polymerase chain reaction," <i>Br. J. Haematol.</i> , 108:132-139, 2000.
	C21	Yamakami <i>et al.</i> , "PCR detection of DNA specific for aspergillus species in serum of patients with invasive aspergillosis," <i>J. Clin. Microbiol.</i> , 34(10):2464-2468, 1996.

25354440.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTXC:766US	Serial No. 10/672,300
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Xiang-Yang Han <i>et al.</i>	
		Filing Date: September 26, 2003	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Zerva <i>et al.</i> , "Serum is the preferred clinical specimen for diagnosis of human brucellosis by PCR," <i>J. Clin. Microbiol.</i> , 39(4):1661-1664, 2001.

25354440.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.